BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme
May 10, 2019Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …
Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
May 10, 2019Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …
Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis
May 9, 2019Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK
NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …
Thousands of EU nurses and midwives leave NHS because of Brexit
May 9, 2019Medical Communications NHS, health, hospitals, midwifes, nurses
Nearly 5,000 EU nurses and midwifes have left the NHS over the past two years. The number of EU nationals …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
May 9, 2019Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …
Sanofi’s Dupixent approved in Europe for severe asthma maintenance
May 9, 2019Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma
Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …
Common diabetes drugs have been linked to a ‘flesh-eating’ genital infection
May 9, 2019Medical Communications, Research and Development FG, diabetes, gangrene, health, necrotizing fasciitis
Patients taking some newer diabetes medications – SGLT2 inhibitors – have been warned that they may be at risk of …
Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua
May 8, 2019Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma
Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
May 8, 2019Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …
AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia
May 8, 2019Research and Development AstraZeneca, Calquence, pharma
AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …
US prescription drugs most expensive in world, analysis shows
May 8, 2019Research and Development Drug pricing, Japan, Ontario, UK, US, prescription drugs
Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to …
Number of GPs in decline for first time in 50 years
May 8, 2019Manufacturing and Production, Research and Development GP, NHS, pharma, public health
The number of GPs has been in decline, year on year, since 2014. The decline marks the first sustained fall …
Mohammed Dar becomes third MedImmune exec to join Immunocore
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
MedImmune’s Vice President of Clincial Development Oncology, Mohammed Dar has joined British biotech Immunocore as the company’s new CMO. Dar …
ABPI names Novartis’ Haseeb Ahmad as new President
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Novartis, appointment, pharma
The Association of the British Pharmaceutical Industry (ABPI) has revealed the appointment of a new President: Haseeb Ahmad will assume …
Gilead’s CFO and Executive Vice President to depart in 2020
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma
Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …
Will mobile phones save the NHS?
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, feature, mhealth, mobile health, pharma
The NHS is sick. According to politicians and NHS chiefs, the cure involves a strong dose of mHealth. Louis Goss …
Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS
May 7, 2019Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma
Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …
Lundbeck acquire Abide Therapeutics in deal worth $400 million
May 7, 2019Manufacturing and Production, Sales and Marketing Abide Therapeutics, Lundbeck, endocannabinoid system, neuropathic pain, tourette's
Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million. …
GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial
May 7, 2019Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc
GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …
FDA approves first two drugs for transthyretin amyloid cardiomyopathy
May 7, 2019Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma
The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
